Navigation Links
Greenphire's ClinCard Technology Platform selected by Bavarian Nordic for Major Vaccine Trial
Date:3/13/2013

KING OF PRUSSIA, Pa., March 13, 2013 /PRNewswire-iReach/ -- Greenphire, the industry-leading provider of payment technologies for the clinical trials industry, today announced that Bavarian Nordic, a vaccine-focused biotechnology company based in Denmark, will use Greenphire's ClinCard Technology Platform in a large, Phase III vaccine trial.  The trial will take approximately 1 year and involve 35 investigative sites and more than 4,000 subjects.

Greenphire's ClinCard system will allow Bavarian Nordic to streamline its clinical payment process for the trial, reducing the administrative burden on investigative sites required for reimbursing subjects.  The system will also enable sites to provide easily accessible, real-time payments to subjects throughout the trial, which has been proven to increase subject retention and compliance.

"Bavarian Nordic is looking forward to collaborating with Greenphire to ensure that payments to the 4,000 subjects involved in this trial will impose a minimal burden on the 35 participating investigative sites and will be easy for subjects to use, helping sites to increase subject retention and compliance," said Siegfried Rösch, Director of Clinical Operations at Bavarian Nordic.

"We are delighted to be working with Bavarian Nordic and to be implementing our ClinCard technology platform that will ensure all subjects involved in this trial receive payments and reimbursements quickly and with reduced cost, risk, and administrative processes," said Sam Whitaker , CEO and Co-Founder of Greenphire, "Bavarian Nordic's decision to use the ClinCard system is an example of how Greenphire's vision for clinical trial payments is increasingly accepted within the global clinical trials industry."

The ClinCard System combines global electronic payment technology with real-time messaging functionality to automate clinical trial payments made to trial subjects.  Payments are delivered through electronic transfers to a reloadable branded debit card or directly to a subject-specified bank account. The ClinCard System enables subjects to access their funds securely and in real-time. Trial sponsors are able to track and report all payments made from a web-based portal in addition to automating the execution of localized trial-specific messaging to the subject via text, email, or automated voice messages.  The ClinCard system reduces costs associated with subject payments by up to 60%, reduces administrative steps by 90%, and has demonstrated increased subject retention by as much as 12%. 

For further information on Greenphire and its innovative solutions please email: sales@greenphire.com, call +1 215-609-4640 or visit www.greenphire.com.

About Greenphire

Greenphire is the industry's leading provider of clinical payment technology, designed to change the way research professionals work. We leverage our proprietary workflow automation and advanced web‐based payment technologies to help our clients improve operational efficiency, reduce costs, mitigate regulatory risks, increase subject retention and compliance, and produce quantifiable results that improve clinical operations and strategic planning. Learn more at www.greenphire.com.

About Bavarian Nordic

Bavarian Nordic is a vaccine-focused biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline targets cancer and infectious diseases, and includes ten development programs. In oncology, the company's lead program is PROSTVAC®, a therapeutic vaccine candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial and is being developed under a collaboration agreement with the  National Cancer Institute. In clinical Phase 1 and Phase 2 trials, PROSTVAC® has been tested in nearly 600 patients. In infectious diseases, the company's lead program is IMVAMUNE®, a non-replicating smallpox vaccine candidate that is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. For more information, visit www.bavarian-nordic.com

Media Contact: Shana Jalbert Greenphire, (215) 948-9260, shana.jalbert@greenphire.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Greenphire
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Verdad Media’s Unique MANIS Technology Means Better Reputation Management Results for Clients
2. The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnologys CYT003 for the Treatment of Allergic Asthma
3. Top Ten Suppliers of Synthetic Biology Technology
4. FOR Breaks New Ground with 3D Printed Implant Technology Webinar
5. Cytos Biotechnology Strengthens Management Team
6. Gregory Raupp Appointed Director of MacroTechnology Works at Arizona State University to Advance Flexible Electronics and Manufacturing
7. Indigo Biosystems Nominated for Two TechPoint Mira Awards for Technology Excellence and Innovation
8. New player in electron field emitter technology makes for better imaging and communications
9. DuPont Pioneer and Mendel Biotechnology, Inc. Collaborate to Improve Water Use Efficiency and Photosynthesis in Corn
10. Personal Genome Diagnostics Inc. Licenses Genome-Mapping Technology from Johns Hopkins University and Expands Its Cancer Genome Analysis Business
11. Computer Review Announces New Tools to Deal with the Flood of Information from the Biotechnology Sector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... -- Dante Labs announced today the offer of whole genome sequencing ... American individuals have been able to access WGS at $1,000, ... below EUR 1,000. The sequencing includes bioinformatics analysis ... make informed decisions about disease monitoring, prevention, nutrition, exercise, health ... ...
(Date:4/21/2017)... ... April 21, 2017 , ... Having worked on the ... Formaspace is pleased to introduce it to top lab design architects from around the ... Turk and VP of Industrial Design and Engineering Greg Casey will be at the ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... and related applications were the focus of researchers, engineers, product developers, and industry ... in Anaheim. , Sponsored by SPIE, the international society for optics and ...
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick Innovative Technology Center, Inc. ... bio and technology start-ups, is hosting “Celebration Friday” (a festive gathering highlighting client ... with libations and networking at 3:30 p.m. at FITCI’s 4539 Metropolitan Court location, ...
Breaking Biology Technology:
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):